233 related articles for article (PubMed ID: 3882737)
41. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma.
Lombardi M; Lupi I; Cosottini M; Rossi G; Manetti L; Raffaelli V; Sardella C; Martino E; Bogazzi F
Horm Metab Res; 2014 Dec; 46(13):939-42. PubMed ID: 25230324
[TBL] [Abstract][Full Text] [Related]
42. Management of prolactinomas associated with very high serum prolactin levels.
Barrow DL; Mizuno J; Tindall GT
J Neurosurg; 1988 Apr; 68(4):554-8. PubMed ID: 3351583
[TBL] [Abstract][Full Text] [Related]
43. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size.
Oppizzi G; Liuzzi A; Chiodini P; Dallabonzana D; Spelta B; Silvestrini F; Borghi G; Tonon C
J Clin Endocrinol Metab; 1984 Jun; 58(6):988-92. PubMed ID: 6725515
[TBL] [Abstract][Full Text] [Related]
44. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases.
Dallabonzana D; Spelta B; Oppizzi G; Tonon C; Luccarelli G; Chiodini PG; Liuzzi A
J Endocrinol Invest; 1983 Feb; 6(1):47-50. PubMed ID: 6841916
[TBL] [Abstract][Full Text] [Related]
45. Bromocriptine reduction of prolactinoma size.
Corenblum B; Hanley DA
Fertil Steril; 1981 Dec; 36(6):716-9. PubMed ID: 7308514
[TBL] [Abstract][Full Text] [Related]
46. Prolactinomas and optic nerve compression: disappearance of suprasellar extension and visual recovery after two weeks bromocriptine treatment.
Woodhouse NJ; Khouqueer F; Sieck JO
Horm Res; 1981; 14(3):141-7. PubMed ID: 7286886
[TBL] [Abstract][Full Text] [Related]
47. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
48. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
49. Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study.
Bassetti M; Spada A; Pezzo G; Giannattasio G
J Clin Endocrinol Metab; 1984 Feb; 58(2):268-73. PubMed ID: 6693536
[TBL] [Abstract][Full Text] [Related]
50. [Bromocriptine for prolactin-secreting macroadenomas of the pituitary].
Landman L; Spindel A; Tal Y; Bar-Meir A; Sharf M; Dickstein G
Harefuah; 1987 Oct; 113(7-8):156-9. PubMed ID: 3428740
[No Abstract] [Full Text] [Related]
51. Treatment of patients with prolactinomas.
Werder Kv; Fahlbusch R; Landgraf R; Pickardt CR; Rjosk HK; Scriba PC
J Endocrinol Invest; 1978 Jan; 1(1):47-58. PubMed ID: 755842
[TBL] [Abstract][Full Text] [Related]
52. [Effect of tamoxifen on the treatment of pituitary adenomas with bromocriptine].
Yamashita M; Hirakawa T; Tashiro Y; Matsuda T; Kibe M; Fukushima T; Tomonaga M
No Shinkei Geka; 1987 Jan; 15(1):65-72. PubMed ID: 3822068
[TBL] [Abstract][Full Text] [Related]
53. Visual function improvement in patients with macroprolactinomas treated with bromocriptine.
Lesser RL; Zheutlin JD; Boghen D; Odel JG; Robbins RJ
Am J Ophthalmol; 1990 May; 109(5):535-43. PubMed ID: 2333917
[TBL] [Abstract][Full Text] [Related]
54. Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study.
Bergström M; Muhr C; Lundberg PO; Bergström K; Gee AD; Fasth KJ; Långström B
J Comput Assist Tomogr; 1987; 11(5):815-9. PubMed ID: 3498743
[TBL] [Abstract][Full Text] [Related]
55. Prolactin-secreting adenomas: the preoperative response to bromocriptine treatment and surgical outcome.
Hubbard JL; Scheithauer BW; Abboud CF; Laws ER
J Neurosurg; 1987 Dec; 67(6):816-21. PubMed ID: 3681421
[TBL] [Abstract][Full Text] [Related]
56. Serum gonadotrophin pulsatile secretion in men with Prl-secreting and non-secreting pituitary tumours.
Ambrosi B; Giovine C; Nava C; Elli R; Faglia G
Acta Endocrinol (Copenh); 1985 May; 109(1):1-6. PubMed ID: 3923752
[TBL] [Abstract][Full Text] [Related]
57. A human pituitary adenoma secreting thyrotropin and prolactin: immunohistochemical, biochemical, and cell culture studies.
Jaquet P; Hassoun J; Delori P; Gunz G; Grisoli F; Weintraub BD
J Clin Endocrinol Metab; 1984 Nov; 59(5):817-24. PubMed ID: 6480809
[TBL] [Abstract][Full Text] [Related]
58. Hyperprolactinaemia in males with and without pituitary macroadenomas.
Spark RF; Wills CA; O'Reilly G; Ransil BJ; Bergland R
Lancet; 1982 Jul; 2(8290):129-32. PubMed ID: 6123841
[TBL] [Abstract][Full Text] [Related]
59. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
60. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment.
Chiodini P; Liuzzi A; Cozzi R; Verde G; Oppizzi G; Dallabonzana D; Spelta B; Silvestrini F; Borghi G; Luccarelli G; Rainer E; Horowski R
J Clin Endocrinol Metab; 1981 Oct; 53(4):737-43. PubMed ID: 7287863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
